Celladon Corp (CLDN) 13.59 $CLDN Nasdaq stocks posting

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:04 PM

Celladon Corp (CLDN) 13.59 $CLDN

Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 22, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), APTO: 5.94 (-0.53), ALDX: 9.30 (-1.45), ASMB: 16.78 (-2.76), CLDN: 13.59 (-2.77), APS.TO: 7.25 (-0.65), ADTN: 16.61 (-1.92), CREE: 32.36 (-3.04)

First Week of CLDN December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:38AM CDT
Investors in Celladon Corp saw new options become available this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the...
CLDN: 13.59 (-2.77)

Celladon trends lower on bearish article
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:23AM CDT

CLDN: 13.59 (-2.77)

Celladon: CUPID-2 Is Likely To Fail
Blair O'Neill - Seeking Alpha - Wed Apr 22, 8:21AM CDT
Much has been said among analysts ( here and here ), and Seeking Alpha authors ( here and here ), about Celladon's (NASDAQ: CLDN ) MYDICAR's monumental upside if the upcoming Phase 2 trial results are positive. However, very little has been said...
CLDN: 13.59 (-2.77)

Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)

Celladon: A Good Deal, And A Rare Buy-Write Opportunity
Jason Ditz - at Seeking Alpha - Mon Apr 20, 7:25AM CDT

CLDN: 13.59 (-2.77)

Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 1:20PM CDT
The report "Cardiomyopathy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopat...eport.html .
GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), CLDN: 13.59 (-2.77), NVS: 103.45 (-0.62)

Celladon (CLDN) Shows Strength: Stock Moves Up 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose almost 10% on the day.
CLDN: 13.59 (-2.77), AFFX: 12.57 (-0.13)

2 Speculative Biotechs That Could Be Well Worth the Risk
George Budwell, The Motley Fool - Motley Fool - Tue Apr 14, 5:59AM CDT
Biotech stocks can produce stunning returns in short order, especially clinical-stage companies working on game-changing drugs or medical devices. These stocks are some of the riskier types of assets, though, frequently plummeting on negative...
QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), EIDO: 27.75 (+0.22), EXEL: 3.12 (+0.05)

UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 136.49 (+1.22), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21)

Why uniQure N.V. Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Apr 06, 9:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the Dutch gene-therapy company uniQure ...
BLUE: 136.49 (+1.22), JNJ: 100.43 (+0.13), QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)

3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.49 (+1.22), IMS: 27.73 (+0.04), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), CLDN: 13.59 (-2.77), ABBV: 64.52 (+0.91)

Has the Biotech Bubble Already Popped?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 04, 8:59AM CDT
During the last couple of years, it seemed that you could pick almost any biotech stock and end up making jaw-dropping gains. The Nasdaq Biotech Index , for instance, has nearly tripled in value since 2010: This parabolic rise has generated...
DVAX: 23.41 (-0.07), INO: 10.39 (-0.09), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ARWR: 6.88 (+0.14), SRPT: 13.52 (+0.04), IBB: 363.84 (-0.66), CLDN: 13.59 (-2.77), CELG: 115.54 (+0.72)

Why Shares in Celladon Corp Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 31, 12:28PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Celladon Corp dropped by as...
CLDN: 13.59 (-2.77)

Celladon's (CLDN) CEO Krisztina Zsebo on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 31, 9:18AM CDT

CLDN: 13.59 (-2.77)

Celladon reports 4Q loss
Automated Insights - Tue Mar 31, 9:01AM CDT
SAN DIEGO (AP) _ Celladon Corp. (CLDN) on Tuesday reported a loss of $11.3 million in its fourth quarter.
CLDN: 13.59 (-2.77)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT

GV: 1.67 (-0.04), CANF: 2.12 (+0.17), SNTA: 2.97 (+0.01), BCRX: 10.62 (-0.09), GBSN: 4.98 (+1.44), TCK: 12.87 (-0.03), CHTR: 184.88 (-1.93), DANG: 8.96 (+0.06), CLDN: 13.59 (-2.77), REXX: 4.77 (-0.04), MOV: 30.62 (-0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Memory Growth Pushes Limits at GMIF2026 Summit

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Melrose Fire Station Reaches Steel Topping Milestone

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

DKS Facing Class Action Over Stock Slump Allegations

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Accuray, Samsung Push Boundaries with Imaging Deal

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Salveo Home Care Faces Class Action Over Labor Violations

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...